Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for atrial fibrillation symptoms in patients with depressive symptoms
ACTRN12623000227695Phase 3Not yet recruiting
- Sponsor
- Melbourne Health
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) and major depressive disorder (MDD) comparing Escitalopram with Placebo (2 arms). Primary endpoint: Change in AF Effect on Quality of Life (AFEQT) score. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
escitalopram
03
Conditions
Atrial fibrillation (AFib)major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12623000227695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000227695.